Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal...
CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (NASDAQ: APLS) announced today the dosing of the first...
globenewswire.com